Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.
about
Development of an algorithm for production of inactivated arbovirus antigens in cell cultureVaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in MicePre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow feverVaccination strategies against Zika virusElderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort studyBCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster modelA flow cytometry-based assay for quantifying non-plaque forming strains of yellow fever virus.Yellow Fever outbreaks in unvaccinated populations, Brazil, 2008-2009Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.Transcriptome sequencing and development of an expression microarray platform for liver infection in adenovirus type 5-infected Syrian golden hamsters.Repeated in vivo stimulation of T and B cell responses in old mice generates protective immunity against lethal West Nile virus encephalitisDevelopment of a new hydrogen peroxide–based vaccine platform.Experimental therapies for yellow feverBalancing the Efficacy and Safety of Vaccines in the Elderly.Vaccines for viral hemorrhagic fevers--progress and shortcomingsAdvances and controversies in yellow fever vaccinationVaccine and adjuvant design for emerging viruses: mutations, deletions, segments and signaling.Vaccination of travelers: how far have we come and where are we going?Review of the risks and benefits of yellow fever vaccination including some new analyses.What a rheumatologist needs to know about yellow fever vaccine.Production of a Sindbis/Eastern Equine Encephalitis chimeric virus inactivated cell culture antigen.Current status and future prospects of yellow fever vaccines.Dose site reactions and related findings after vaccine administration in safety studies.Questions regarding the safety and duration of immunity following live yellow fever vaccination.Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine.The 17D-204 and 17DD yellow fever vaccines: an overview of major similarities and subtle differences.Plant-Produced Subunit Vaccine Candidates against Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against Viral Challenge in Animal Models.Cross-neutralisation of viruses of the tick-borne encephalitis complex following tick-borne encephalitis vaccination and/or infection.GelbfieberProcess intensification of EB66® cell cultivations leads to high-yield yellow fever and Zika virus productionImmunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster ModelZika Virus Vaccines: Challenges and Perspectives
P2860
Q24289426-D30536EA-DC95-4437-ACC9-813D7A1608E0Q27303766-4296ECAC-D8F2-4BC3-8418-4433D98304A6Q28740522-912D0D44-899A-49FF-A35E-9738D5D921B0Q29571224-189DC299-F8A1-44BC-A4FD-3611578ED416Q33352692-694941B1-95CB-4524-B51D-C360D5A5A3BAQ34041804-BC8D652E-4A5F-4A1B-8D9F-18F0974B18A3Q34426711-90C09BCA-961C-4CA7-99B4-991E54404459Q35119844-EB7BDB91-143B-4287-B304-241FAF5B5012Q35141448-7DB062DA-6604-4786-A1AB-251B32B66C5AQ36202563-4596578C-4BB0-40BD-97D2-2E884ECF3664Q36411126-0C361FEC-33B3-4B40-9E9F-E94CB8E8284AQ36423118-7981CB92-19FA-4BC2-868A-213CB141A824Q36586306-209FA598-7674-4DD2-A9A4-BE28F12B9F21Q36740019-1C782EAD-328F-4010-8458-F403ADFE7C47Q37096221-36C8F064-A224-4ED6-8403-8178A047793AQ37709619-46FFDA1B-965C-41A1-B838-0E249FA53E97Q37884343-F5154E0C-FA82-4260-AB7F-BF160A3A717EQ37951528-E3F264D8-0F5A-42DC-A084-080E39593DB6Q38006992-D6D891BE-A5AD-4B66-B7AF-2651103602F6Q38121741-666B7E99-B215-479B-A8C4-E0199B881175Q38424029-94BC3EF4-8B26-4A1B-95B4-2F2A2F0AD2A1Q38586294-2250D8D9-6F8B-49D2-B8A6-566142052D5FQ38770307-E92331C0-7C4F-43C8-81D9-DD96FF93DA93Q39706701-9286E89B-E126-4694-9630-B4B1B85F7B92Q40423085-810E1DD0-5E4B-49B9-B117-D431BA54DB57Q46239950-B106BA29-3AE9-47AA-8CC8-55C6B50A08F5Q46634823-1F4AACE2-FF3A-43E6-B78C-A8F64277BD26Q47096633-E3FBFCDF-89D3-49A4-BC41-C7CE853EEF7EQ55109796-78A9590F-C312-43FC-BE68-CEED4EDDAAA9Q56341510-F604490B-B20B-497A-B8EC-600BC2A56BA3Q56395905-32391988-D881-43DD-ADC5-4337716DAC74Q58742686-5A6BEDE1-AFC3-4A31-9029-0BE265A2359A
P2860
Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Inactivated yellow fever 17D v ...... icity and protective activity.
@en
type
label
Inactivated yellow fever 17D v ...... icity and protective activity.
@en
prefLabel
Inactivated yellow fever 17D v ...... icity and protective activity.
@en
P2093
P1433
P1476
Inactivated yellow fever 17D v ...... icity and protective activity.
@en
P2093
Alicja Brown
Cynthia K Lee
David W Beasley
Dennis W Trent
Douglas M Watts
Edward Hayman
Elizabeth Fowler
Gavin C Bowick
Joseph Crowell
Joseph Makowiecki
P304
P356
10.1016/J.VACCINE.2010.03.023
P407
P577
2010-03-26T00:00:00Z